Company: INKT
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0000950170-25-055881
Chunk: 27

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 27
---
 plans in 2024, but such participation was solely related to the services the named executive officer provided to that entity and awards under those plans are not disclosed or otherwise discussed in this proxy statement.

Each of Drs. Buell and van Dijk received Company equity awards under the 2021 Plan during fiscal year 2024, as follows:

On January 16, 2024, Dr. Buell was granted an option to purchase 50,000 shares of our common stock. This option is subject to time-based vesting and vested as to one-third (1/3) of the underlying shares on January 16, 2025 and vests as to the remaining two-thirds (2/3) of the underlying shares in eight equal quarterly installments thereafter, generally subject to Dr. Buell’s continued employment with us or our affiliates through the applicable vesting date. On January 16, 2024, Dr. Buell was also granted an option to purchase 66,091 shares of our common stock in respect of her 2023 annual bonus, which was delivered in the form of time-based options in lieu of cash. This option vested as to 50% of the underlying shares on June 27, 2024 and as to 50% of the underlying shares on September 27, 2024.

<div align='center'>18</div>

On January 16, 2024, Dr. van Dijk was granted an option to purchase 1,500 shares of our common stock. This option is subject to time-based vesting and vested as to one-third (1/3) of the underlying shares on January 16, 2025 and vests as to the remaining two-thirds (2/3) of the underlying shares in eight equal quarterly installments thereafter, generally subject to Dr. van Dijk's continued service to us or our affiliates through the applicable vesting date. On January 16, 2024, Dr. van Dijk was also granted an option to purchase 17,107 shares of our common stock in respect of his 2023 annual bonus, which was delivered in the form of time-based options in lieu of cash. This option vested as to 50% of the underlying shares on June 27, 2024 and as to 50% of the underlying shares on September 27, 2024.

Ms. Klaskin did not receive any Company equity awards during fiscal year 2024.

Policies and Practices Related to the Timing of